“The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.”
All entries for: Biologic
August 4, 2023
Gilead
Negative Outlook
Foster City, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
August 3, 2023
Alnylam
Negative Outlook
Cambridge, MA
1,001-5,000 employees
1001-5000 employees
Disease Area: Multiple
Drug Type: Biologic
August 3, 2023
Regeneron
Neutral Outlook
Tarrytown, NY
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
August 3, 2023
IGM Biosciences
Negative Outlook
Mountain View, CA
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 2, 2023
Coherus BioSciences
Negative Outlook
Camarillo, CA
201-500 employees
201-500 employees
Disease Area: Oncology
Drug Type: Biologic
August 2, 2023
Beigene
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Oncology
Drug Type: Biologic
July 27, 2023
Bristol Myers Squibb
Negative Outlook
Princeton, NJ
10,001-50,000 employees
10001-50000 employees
Drug Type: Biologic, Small Molecule
July 25, 2023
Biogen
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
May 19, 2023
Novartis
Discontinued Drug, Discontinued Research
Basel, Switzerland
50,001+ employees
50001+ employees
“In an interview with Barron’s, Narasimhan said some of the programs which Novartis discontinued were cancer drugs in early-stage trials.
“We saw assets that were noncompetitive, or we thought might be unduly affected by IRA,” Narasimhan said.
The CEO said “a few” of the cancer drugs being dropped from Novartis’s pipeline were discontinued because of price negotiations.
The drugs that were dropped were “in areas where we didn’t think we could do a development plan that would allow us to successfully get the drug in patients, and fully developed across the range of indications within nine years,” Narasimhan said. They were in cancers particularly affecting the elderly, given that Medicare treats adults aged 65 and older.”
2 Discontinued Drugs: unnamed cancer drugs
2 Discontinued Research Programs
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
May 12, 2023
IGM Biosciences
Negative Outlook
Mountain View, CA
201-500 employees
201-500 employees
“The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.”
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
